Advancing mRNA-based drug development and vaccine manufacturing
Shared by Parexel experts, Christiane Niederlaender, Cecil Nick, and Sinan Sarac covering on the topics of:
Section 1 - Overview of mRNA Product Manufacturing Challenges
Section 2 - Optimizing the Path to Regulatory Approval for Novel Vaccine
Section 3 - Accelerating Approval of mRNA vaccines for Oncology Drug development
Related Insights
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Blog
FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers
Mar 31, 2026
Playbook
Preparing clinical infrastructure for radiopharmaceutical trials
Mar 11, 2026
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Related Insights
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Blog
FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers
Mar 31, 2026
Playbook
Preparing clinical infrastructure for radiopharmaceutical trials
Mar 11, 2026
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026